Scarica l'app Stockscreener
1.18
2.61%
0.03
Pre-mercato:
1.17
-0.01
-0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GERN Giù?
Forum
Previsione
Precedente Chiudi:
$1.15
Aprire:
$1.16
Volume 24 ore:
10.26M
Relative Volume:
0.63
Capitalizzazione di mercato:
$756.99M
Reddito:
$196.12M
Utile/perdita netta:
$-69.59M
Rapporto P/E:
-11.31
EPS:
-0.1043
Flusso di cassa netto:
$-126.13M
1 W Prestazione:
+5.36%
1M Prestazione:
-8.53%
6M Prestazione:
-11.94%
1 anno Prestazione:
-23.87%
Intervallo 1D:
$1.14
$1.18
Intervallo di 1 settimana:
$1.08
$1.22
Portata 52W:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Nome
Geron Corp
Settore
Industria
Telefono
(650) 473-7700
Indirizzo
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.18 | 737.75M | 196.12M | -69.59M | -126.13M | -0.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-05-08 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Iniziato | Leerink Partners | Outperform |
| 2024-04-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | Iniziato | TD Cowen | Buy |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2023-09-12 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-28 | Iniziato | Goldman | Neutral |
| 2022-10-28 | Iniziato | Wedbush | Outperform |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2021-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Ripresa | B. Riley Securities | Buy |
| 2020-08-03 | Iniziato | Stifel | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-09-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-04-09 | Aggiornamento | Needham | Hold → Buy |
| 2019-01-31 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | Reiterato | FBR & Co. | Outperform |
| 2016-09-13 | Reiterato | FBR Capital | Outperform |
| 2015-12-07 | Reiterato | Piper Jaffray | Overweight |
| 2015-04-21 | Iniziato | Oppenheimer | Outperform |
| 2014-06-12 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-03-12 | Downgrade | MLV & Co | Buy → Hold |
| 2013-12-10 | Reiterato | MLV & Co | Buy |
| 2013-12-10 | Aggiornamento | Needham | Hold → Buy |
| 2013-11-08 | Reiterato | MLV & Co | Buy |
| 2013-10-16 | Iniziato | MLV & Co | Buy |
| 2012-08-30 | Iniziato | Stifel Nicolaus | Buy |
| 2012-06-28 | Iniziato | Needham | Hold |
Mostra tutto
Geron Corp Borsa (GERN) Ultime notizie
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
GERN Stock Builds Momentum On Strong RYTELO Data - StocksToTrade
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch - AD HOC NEWS
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp stock (US3741631036): Focus on valuation as short interest eases - AD HOC NEWS
GERN Stock Chart | GERON CORP (NASDAQ:GERN) - ChartMill
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN) - Yahoo Finance
GERN SEC FilingsGeron Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
Geron plans Goldman Sachs healthcare fireside chat, webcast June 8 - Stock Titan
1GERN.MI Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (BIT:1GERN) - ChartMill
Geron Shareholders Expand Equity Plan and Elect Directors - The Globe and Mail
Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan - Stock Titan
Geron (NASDAQ: GERN) director awarded 220,000 options at $1.26 strike - Stock Titan
Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26 - Stock Titan
Geron (GERN) awards director Susan Molineaux 220,000 stock options - Stock Titan
Geron (GERN) director granted 220,000 stock options at $1.26 - Stock Titan
Geron (GERN) director Dawn Carter Bir awarded 220,000 stock options - Stock Titan
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
GERN: All proposals passed; clinical and commercial strategies advancing, with key trial data ahead - TradingView
Geron Corporation’s SWOT analysis: biotech stock faces sales headwinds - Investing.com
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus - AD HOC NEWS
Five new Geron hires receive options for 333,750 shares - Stock Titan
Shareholders of Geron Corporation Should Contact The Gross Law F - GuruFocus
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026) - Stock Titan
TradingKey - TradingKey
Geron reports Q1 revenue growth and updates on blood cancer drug progress. - Pluang
Geron Corporation Announces Positive Real-World Evidence Study of RYTELO® in Lower-Risk Myelodysplastic Syndromes Ahead of EHA 2026 Presentations - Quiver Quantitative
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - ChartMill
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy? - Insider Monkey
10 Best US Stocks Under $5 to Buy - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Soleus group discloses 41.51M GERN shares (6.5%) — Soleus/Guy Levy - Stock Titan
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q1 2026 Earnings Call Transcript - Insider Monkey
Geron Corporation (NASDAQ:GERN): Is Breakeven Near? - Moomoo
Can Geron’s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential? - simplywall.st
Geron (GERN) Q1 2026 Earnings Call Transcript - AOL.com
Geron Corporation Q1 2026 Financial Results: Revenue, Net Loss, and SEC Filing Insights - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Geron Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Geron: Q1 Earnings Snapshot - theheraldreview.com
[10-Q] GERON CORP Quarterly Earnings Report - Stock Titan
Geron Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Geron (GERN) reports Q1 loss, beats revenue estimates - MSN
Geron Q1 Earnings Call Highlights - Yahoo Finance
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues - ChartMill
Geron Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Geron Corp Azioni (GERN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Geron Corp Azioni (GERN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER |
Feb 18 '26 |
Sale |
1.94 |
9,855 |
19,119 |
17,645 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):